Search

Your search keyword '"Maki, A. G."' showing total 2,385 results
Start Over Author "Maki, A. G."
2,385 results on '"Maki, A. G."'

2. International Multicenter Retrospective Study From the Ultra-rare Sarcoma Working Group on Low-grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma, and Hybrid Forms: Outcome of Primary Localized Disease

Author

Giani, Claudia, Salawu, Abdulazeez, Ljevar, Silva, Denu, Ryan A., Napolitano, Andrea, Palmerini, Emanuela, Connolly, Elizabeth A., Ogura, Koichi, Wong, Daniel D., Scanferla, Roberto, Rosenbaum, Evan, Bajpai, Jyoti, Li, Zola Chia-Chen, Bae, Susie, D’Ambrosio, Lorenzo, Bialick, Steve, Wagner, Andrew J., Lee, Alexander T.J., Koseła-Paterczyk, Hanna, Baldi, Giacomo G., Brunello, Antonella, Lee, Yeh Chen, Loong, Herbert H., Boikos, Sosipatros, Campos, Fernando, Cicala, Carlo M., Maki, Robert G., Hindi, Nadia, Figura, Costanza, Almohsen, Shahd S., Patel, Sheyaskumar, Jones, Robin L., Ibrahim, Toni, Karim, Rooshdiya, Kawai, Akira, Carey-Smith, Richard, Boyle, Richard, Taverna, Silvia M., Lazar, Alexander J., Demicco, Elizabeth G., Bovee, Judith V.M.G., Dei Tos, Angelo P., Fletcher, Christopher, Baumhoer, Daniel, Sbaraglia, Marta, Schaefer, Inga-Marie, Miceli, Rosalba, Gronchi, Alessandro, and Stacchiotti, Silvia

Published
2025
Full Text
View/download PDF

10. Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma

Author

Gounder, Mrinal M, Agaram, Narasimhan P, Trabucco, Sally E, Robinson, Victoria, Ferraro, Richard A, Millis, Sherri Z, Krishnan, Anita, Lee, Jessica, Attia, Steven, Abida, Wassim, Drilon, Alexander, Chi, Ping, Angelo, Sandra P D’, Dickson, Mark A, Keohan, Mary Lou, Kelly, Ciara M, Agulnik, Mark, Chawla, Sant P, Choy, Edwin, Chugh, Rashmi, Meyer, Christian F, Myer, Parvathi A, Moore, Jessica L, Okimoto, Ross A, Pollock, Raphael E, Ravi, Vinod, Singh, Arun S, Somaiah, Neeta, Wagner, Andrew J, Healey, John H, Frampton, Garrett M, Venstrom, Jeffrey M, Ross, Jeffrey S, Ladanyi, Marc, Singer, Samuel, Brennan, Murray F, Schwartz, Gary K, Lazar, Alexander J, Thomas, David M, Maki, Robert G, Tap, William D, Ali, Siraj M, and Jin, Dexter X

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Genetics, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Biotechnology, Clinical Research, Human Genome, Genetic Testing, Aetiology, 2.1 Biological and endogenous factors, Good Health and Well Being, Biomarkers, Tumor, Bone Neoplasms, Genomics, Humans, Mutation, Osteosarcoma, Prospective Studies, Sarcoma
Abstract

There are more than 70 distinct sarcomas, and this diversity complicates the development of precision-based therapeutics for these cancers. Prospective comprehensive genomic profiling could overcome this challenge by providing insight into sarcomas' molecular drivers. Through targeted panel sequencing of 7494 sarcomas representing 44 histologies, we identify highly recurrent and type-specific alterations that aid in diagnosis and treatment decisions. Sequencing could lead to refinement or reassignment of 10.5% of diagnoses. Nearly one-third of patients (31.7%) harbor potentially actionable alterations, including a significant proportion (2.6%) with kinase gene rearrangements; 3.9% have a tumor mutational burden ≥10 mut/Mb. We describe low frequencies of microsatellite instability (

Published
2022

14. A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study.

Author

Riedel, Richard F, Ballman, Karla V, Lu, Yao, Attia, Steven, Loggers, Elizabeth T, Ganjoo, Kristen N, Livingston, Michael B, Chow, Warren, Wright, Jennifer, Ward, John H, Rushing, Daniel, Okuno, Scott H, Reed, Damon R, Liebner, David A, Keedy, Vicki L, Mascarenhas, Leo, Davis, Lara E, Ryan, Christopher, Reinke, Denise K, and Maki, Robert G

Subjects
Humans, Liposarcoma, Phenylurea Compounds, Pyridines, Protein Kinase Inhibitors, Treatment Outcome, Double-Blind Method, Adult, Aged, Middle Aged, Female, Male, Clinical Research, Clinical Trials and Supportive Activities, Cancer, 6.1 Pharmaceuticals, Oncology & Carcinogenesis, Oncology and Carcinogenesis
Abstract

Lessons learnedThe results from the liposarcoma cohort of SARC024 confirm previously published data and do not support the routine use of regorafenib in this patient population. Continued exploration of novel therapies, including combination approaches, is warranted for a patient population in whom limited treatment options exist.BackgroundRegorafenib is a multitargeted kinase inhibitor with a kinase profile overlapping, but distinct from, pazopanib, an agent approved for recurrent and metastatic non-gastrointestinal stromal tumor (GIST), non-adipocytic soft tissue sarcoma. We conducted a randomized, phase II study of regorafenib versus placebo in refractory liposarcoma patients.MethodsPatients with advanced or metastatic, treatment-refractory liposarcoma were randomized 1:1 to receive regorafenib 160 mg or placebo once daily (3 weeks on, 1 week off). Patients with well-differentiated liposarcoma only were excluded. Crossover for placebo was allowed upon progression. The primary endpoint was progression-free survival (PFS), according to RECIST version 1.1.ResultsForty-eight subjects with liposarcoma (34 dedifferentiated, 12 myxoid/round cell, 2 pleomorphic) were enrolled. Median PFS was 1.87 (95% confidence interval [CI], 0.92-3.67) months for regorafenib versus 2.07 (95% CI, 1.64-3.44) months for placebo; stratified hazard ratio [HR], 0.85 (95% CI, 0.46, 1.58), p = .62. No responses were seen on regorafenib. One PR was observed on placebo. Median overall survival was 6.46 (95% CI, 4.16-23.48) months for regorafenib and 4.89 (95% CI, 3.02-9.77) months for placebo, stratified HR, 0.66 (95% CI, 0.31-1.40), p = .28). Treatment-related adverse events were similar to the known safety profile of regorafenib.ConclusionRegorafenib did not appear to improve PFS in treatment-refractory liposarcoma. No new significant safety signals were observed.

Published
2020

15. A framework for advancing our understanding of cancer-associated fibroblasts

Author

Sahai, Erik, Astsaturov, Igor, Cukierman, Edna, DeNardo, David G, Egeblad, Mikala, Evans, Ronald M, Fearon, Douglas, Greten, Florian R, Hingorani, Sunil R, Hunter, Tony, Hynes, Richard O, Jain, Rakesh K, Janowitz, Tobias, Jorgensen, Claus, Kimmelman, Alec C, Kolonin, Mikhail G, Maki, Robert G, Powers, R Scott, Puré, Ellen, Ramirez, Daniel C, Scherz-Shouval, Ruth, Sherman, Mara H, Stewart, Sheila, Tlsty, Thea D, Tuveson, David A, Watt, Fiona M, Weaver, Valerie, Weeraratna, Ashani T, and Werb, Zena

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, 2.1 Biological and endogenous factors, Animals, Biomarkers, Cancer-Associated Fibroblasts, Cell Plasticity, Clinical Trials as Topic, Disease Susceptibility, Humans, Molecular Targeted Therapy, Neoplasms, Signal Transduction, Stromal Cells, Treatment Outcome, Tumor Microenvironment, Medical and Health Sciences, Oncology & Carcinogenesis, Biomedical and clinical sciences, Health sciences
Abstract

Cancer-associated fibroblasts (CAFs) are a key component of the tumour microenvironment with diverse functions, including matrix deposition and remodelling, extensive reciprocal signalling interactions with cancer cells and crosstalk with infiltrating leukocytes. As such, they are a potential target for optimizing therapeutic strategies against cancer. However, many challenges are present in ongoing attempts to modulate CAFs for therapeutic benefit. These include limitations in our understanding of the origin of CAFs and heterogeneity in CAF function, with it being desirable to retain some antitumorigenic functions. On the basis of a meeting of experts in the field of CAF biology, we summarize in this Consensus Statement our current knowledge and present a framework for advancing our understanding of this critical cell type within the tumour microenvironment.

Published
2020

19. Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma

Author

Berlow, Noah E, Rikhi, Rishi, Geltzeiler, Mathew, Abraham, Jinu, Svalina, Matthew N, Davis, Lara E, Wise, Erin, Mancini, Maria, Noujaim, Jonathan, Mansoor, Atiya, Quist, Michael J, Matlock, Kevin L, Goros, Martin W, Hernandez, Brian S, Doung, Yee C, Thway, Khin, Tsukahara, Tomohide, Nishio, Jun, Huang, Elaine T, Airhart, Susan, Bult, Carol J, Gandour-Edwards, Regina, Maki, Robert G, Jones, Robin L, Michalek, Joel E, Milovancev, Milan, Ghosh, Souparno, Pal, Ranadip, and Keller, Charles

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Human Genome, Networking and Information Technology R&D (NITRD), Rare Diseases, Cancer, Orphan Drug, Bioengineering, Biotechnology, Genetics, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Good Health and Well Being, Animals, Cell Line, Tumor, Computational Biology, Disease Models, Animal, Dogs, Drug Evaluation, Preclinical, Drug Synergism, Drug Therapy, Combination, Female, Heterografts, Humans, Kaplan-Meier Estimate, Mice, Mice, Inbred NOD, Models, Statistical, Precision Medicine, Rhabdomyosarcoma, Alveolar, Artificial intelligence and machine learning, Combination therapy, Computational modeling, Drug screening, High-throughput sequencing, Pediatric cancer, Personalized therapy, Sarcoma, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Epidemiology
Abstract

BackgroundCancer patients with advanced disease routinely exhaust available clinical regimens and lack actionable genomic medicine results, leaving a large patient population without effective treatments options when their disease inevitably progresses. To address the unmet clinical need for evidence-based therapy assignment when standard clinical approaches have failed, we have developed a probabilistic computational modeling approach which integrates molecular sequencing data with functional assay data to develop patient-specific combination cancer treatments.MethodsTissue taken from a murine model of alveolar rhabdomyosarcoma was used to perform single agent drug screening and DNA/RNA sequencing experiments; results integrated via our computational modeling approach identified a synergistic personalized two-drug combination. Cells derived from the primary murine tumor were allografted into mouse models and used to validate the personalized two-drug combination. Computational modeling of single agent drug screening and RNA sequencing of multiple heterogenous sites from a single patient's epithelioid sarcoma identified a personalized two-drug combination effective across all tumor regions. The heterogeneity-consensus combination was validated in a xenograft model derived from the patient's primary tumor. Cell cultures derived from human and canine undifferentiated pleomorphic sarcoma were assayed by drug screen; computational modeling identified a resistance-abrogating two-drug combination common to both cell cultures. This combination was validated in vitro via a cell regrowth assay.ResultsOur computational modeling approach addresses three major challenges in personalized cancer therapy: synergistic drug combination predictions (validated in vitro and in vivo in a genetically engineered murine cancer model), identification of unifying therapeutic targets to overcome intra-tumor heterogeneity (validated in vivo in a human cancer xenograft), and mitigation of cancer cell resistance and rewiring mechanisms (validated in vitro in a human and canine cancer model).ConclusionsThese proof-of-concept studies support the use of an integrative functional approach to personalized combination therapy prediction for the population of high-risk cancer patients lacking viable clinical options and without actionable DNA sequencing-based therapy.

Published
2019

20. A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery

Author

Rosenbaum, Evan, Chugh, Rashmi, Ryan, Christopher W., Agulnik, Mark, Milhem, Mohammed M., George, Suzanne, Jones, Robin L., Chmielowski, Bartosz, Van Tine, Brian A., Tawbi, Hussein, Elias, Anthony D., Read, William L., Budd, G. Thomas, Qin, Li-Xuan, Rodler, Eve T., Hirman, Joe, Weiden, Paul, Bennett, Cathryn M., Livingston, Philip O., Ragupathi, Govind, Hansen, David, D'Angelo, Sandra P., Tap, William D., Schwartz, Gary K., Maki, Robert G., and Carvajal, Richard D.

Published
2022
Full Text
View/download PDF

21. Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments

Author

Stacchiotti, Silvia, Maria Frezza, Anna, Demetri, George D., Blay, Jean-Yves, Bajpai, Jyoti, Baldi, Giacomo G., Baldini, Elizabeth H., Benjamin, Robert S., Bonvalot, Sylvie, Bovée, Judith V.M.G., Callegaro, Dario, Casali, Paolo G., D'Angelo, Sandra P., Davis, Elizabeth J., Dei Tos, Angelo P., Demicco, Elizabeth G., Desai, Jayesh, Dileo, Palma, Eriksson, Mikael, Gelderblom, Hans, George, Suzanne, Gladdy, Rebecca A., Gounder, Mrinal M., Gupta, Abha A., Haas, Rick, Hayes, Andrea, Hohenberger, Peter, Jones, Kevin B., Jones, Robin L., Kasper, Bernd, Kawai, Akira, Kirsch, David G., Kleinerman, Eugenie S., Le Cesne, Axel, Maestro, Roberta, Martin Broto, Javier, Maki, Robert G., Miah, Aisha B., Palmerini, Emanuela, Patel, Shreaskumar R., Raut, Chandrajit P., Razak, Albiruni R.A., Reed, Damon R., Rutkowski, Piotr, Sanfilippo, Roberta G., Sbaraglia, Marta, Schaefer, Inga-Marie, Strauss, Dirk C., Strauss, Sandra J., Tap, William D., Thomas, David M., Trama, Annalisa, Trent, Jonathan C., van der Graaf, Winette T.A., van Houdt, Winan J., von Mehren, Margaret, Wilky, Breelyn A., Fletcher, Christopher D.M., Gronchi, Alessandro, Miceli, Rosalba, and Wagner, Andrew J.

Published
2022
Full Text
View/download PDF

33. Early, precise, and safe clinical evaluation of the pharmacodynamic effects of novel agents in the intact human tumor microenvironment

Author

Gundle, Kenneth R., primary, Rajasekaran, Karthik, additional, Houlton, Jeffrey, additional, Deutsch, Gary B., additional, Ow, Thomas J., additional, Maki, Robert G., additional, Pang, John, additional, Nathan, Cherie-Ann O., additional, Clayburgh, Daniel, additional, Newman, Jason G., additional, Brinkmann, Elyse, additional, Wagner, Michael J., additional, Pollack, Seth M., additional, Thompson, Matthew J., additional, Li, Ryan J., additional, Mehta, Vikas, additional, Schiff, Bradley A., additional, Wenig, Barry I., additional, Swiecicki, Paul L., additional, Tang, Alice L., additional, Davis, Jessica L., additional, van Zante, Annemieke, additional, Bertout, Jessica A., additional, Jenkins, Wendy, additional, Turner, Atticus, additional, Grenley, Marc, additional, Burns, Connor, additional, Frazier, Jason P., additional, Merrell, Angela, additional, Sottero, Kimberly H. W., additional, Derry, Jonathan M. J., additional, Gillespie, Kate C., additional, Mills, Bre, additional, and Klinghoffer, Richard A., additional

Published
2024
Full Text
View/download PDF

36. Surgical Management of Sarcoma Metastatic to Liver

Author

Ecker, Brett L., Maki, Robert G., Cavnar, Michael J., and DeMatteo, Ronald P.

Abstract

Sarcomas are rare mesenchymal tumors with a propensity for hematogenous metastasis. Gastrointestinal stromal tumor (GIST) is the most common histologic subtype and the most common source of hepatic metastases. In the case of metastatic GIST, neoadjuvant imatinib can be used as a selection tool for the judicious application of surgery, where treatment-responsive patients who undergo resection to prevent the development of treatment-resistant clones have associated 10-year actuarial survival of 40%. Further advances for many of the non-GIST sarcoma subtypes will depend on the development of improved systemic therapies and evaluation of their activity in subtype or molecularly defined trials.

Published
2025
Full Text
View/download PDF

44. Gastrointestinal Stromal Tumors

Author

Brennan, Murray F., Antonescu, Cristina R., Alektiar, Kaled M., Maki, Robert G., Brennan, Murray F., Antonescu, Cristina R., Alektiar, Kaled M., and Maki, Robert G.

Published
2016
Full Text
View/download PDF

45. Selected Benign Tumors

Author

Brennan, Murray F., Antonescu, Cristina R., Alektiar, Kaled M., Maki, Robert G., Brennan, Murray F., Antonescu, Cristina R., Alektiar, Kaled M., and Maki, Robert G.

Published
2016
Full Text
View/download PDF

47. Extraskeletal Osteogenic Sarcoma

Author

Brennan, Murray F., Antonescu, Cristina R., Alektiar, Kaled M., Maki, Robert G., Brennan, Murray F., Antonescu, Cristina R., Alektiar, Kaled M., and Maki, Robert G.

Published
2016
Full Text
View/download PDF

48. Reactive Lesions

Author

Brennan, Murray F., Antonescu, Cristina R., Alektiar, Kaled M., Maki, Robert G., Brennan, Murray F., Antonescu, Cristina R., Alektiar, Kaled M., and Maki, Robert G.

Published
2016
Full Text
View/download PDF

49. Mostly Benign/Rarely Metastasizing

Author

Brennan, Murray F., Antonescu, Cristina R., Alektiar, Kaled M., Maki, Robert G., Brennan, Murray F., Antonescu, Cristina R., Alektiar, Kaled M., and Maki, Robert G.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results